Alnylam Pharmaceuticals Inc (ALNY)vsLakewood-Amedex Biotherapeutics Inc. Common Stock (LABT)
ALNY
Alnylam Pharmaceuticals Inc
$291.37
-0.19%
HEALTHCARE · Cap: $39.26B
LABT
Lakewood-Amedex Biotherapeutics Inc. Common Stock
$3.43
-4.60%
HEALTHCARE · Cap: $6.21M
Smart Verdict
WallStSmart Research — data-driven comparison
ALNY leads profitability with a 12.6% profit margin vs 0.0%. ALNY earns a higher WallStSmart Score of 65/100 (B-).
ALNY
Strong Buy65
out of 100
Grade: B-
LABT
Avoid17
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.4%
Fair Value
$2363.38
Current Price
$291.37
$2072.01 discount
Intrinsic value data unavailable for LABT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 54 in profit
Revenue surging 96.4% year-over-year
Strong operational efficiency at 23.0%
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 36.2x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.50 suggests the stock is reasonably priced for its growth.
Bull Case : LABT
The strongest argument for LABT centers on Debt/Equity.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, Debt/Equity, P/E Ratio. A P/E of 74.1x leaves little room for execution misses.
Bear Case : LABT
The primary concerns for LABT are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ALNY profiles as a growth stock while LABT is a value play — different risk/reward profiles.
ALNY is growing revenue faster at 96.4% — sustainability is the question.
ALNY generates stronger free cash flow (49M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ALNY scores higher overall (65/100 vs 17/100) and 96.4% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Lakewood-Amedex Biotherapeutics Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Labtec Inc (Ticker: LABT) is a leading biotechnology company focused on pioneering advancements in drug delivery systems and diagnostic solutions. The firm employs innovative technologies and strategic partnerships to tackle significant healthcare challenges, thereby enhancing patient outcomes. With a robust portfolio and a commitment to addressing unmet medical needs, Labtec is strategically positioned for growth in the dynamic biotech landscape, making it an attractive investment opportunity for institutional investors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?